Adaptimmune Therapeutics plc (ADAP): Price and Financial Metrics
ADAP Price/Volume Stats
Current price | $1.47 | 52-week high | $2.05 |
Prev. close | $1.48 | 52-week low | $0.42 |
Day low | $1.36 | Volume | 1,093,100 |
Day high | $1.51 | Avg. volume | 1,954,404 |
50-day MA | $1.19 | Dividend yield | N/A |
200-day MA | $0.86 | Market Cap | 1.46B |
ADAP Stock Price Chart Interactive Chart >
ADAP POWR Grades
- Sentiment is the dimension where ADAP ranks best; there it ranks ahead of 79.88% of US stocks.
- The strongest trend for ADAP is in Stability, which has been heading up over the past 26 weeks.
- ADAP's current lowest rank is in the Momentum metric (where it is better than 10.87% of US stocks).
ADAP Stock Summary
- For ADAP, its debt to operating expenses ratio is greater than that reported by just 16.98% of US equities we're observing.
- As for revenue growth, note that ADAP's revenue has grown 305.3% over the past 12 months; that beats the revenue growth of 98.26% of US companies in our set.
- In terms of volatility of its share price, ADAP is more volatile than 87.44% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to ADAPTIMMUNE THERAPEUTICS PLC are SPCE, PTN, ABEO, SABS, and OCUP.
- ADAP's SEC filings can be seen here. And to visit ADAPTIMMUNE THERAPEUTICS PLC's official web site, go to www.adaptimmune.com.
ADAP Valuation Summary
- In comparison to the median Healthcare stock, ADAP's price/sales ratio is 40.48% lower, now standing at 2.5.
- Over the past 94 months, ADAP's price/sales ratio has gone down 36.7.
Below are key valuation metrics over time for ADAP.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ADAP | 2023-12-29 | 2.5 | 2.0 | -1.9 | -1.2 |
ADAP | 2023-12-28 | 2.2 | 1.8 | -1.6 | -1.0 |
ADAP | 2023-12-27 | 2.3 | 1.9 | -1.7 | -1.0 |
ADAP | 2023-12-26 | 1.9 | 1.5 | -1.4 | -0.7 |
ADAP | 2023-12-22 | 1.6 | 1.3 | -1.2 | -0.5 |
ADAP | 2023-12-21 | 1.5 | 1.2 | -1.1 | -0.4 |
ADAP Growth Metrics
- Its 3 year net income to common stockholders growth rate is now at -66.94%.
- Its 4 year net income to common stockholders growth rate is now at -77.31%.
- Its year over year cash and equivalents growth rate is now at 146.4%.
The table below shows ADAP's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 17.537 | -9.883 | -175.064 |
2022-06-30 | 11.733 | -6.924 | -176.044 |
2022-03-31 | 9.29 | 2.868 | -170.592 |
2021-12-31 | 6.149 | 10.729 | -158.09 |
2021-09-30 | 6.234 | -152.415 | -155.845 |
2021-06-30 | 6.224 | -123.532 | -148.876 |
ADAP's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ADAP has a Quality Grade of C, ranking ahead of 58.13% of graded US stocks.
- ADAP's asset turnover comes in at 0.016 -- ranking 378th of 682 Pharmaceutical Products stocks.
- CALA, ACOR, and INSM are the stocks whose asset turnover ratios are most correlated with ADAP.
The table below shows ADAP's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.016 | 1 | -0.462 |
2021-06-30 | 0.014 | 1 | -0.414 |
2021-03-31 | 0.008 | 1 | -0.374 |
2020-12-31 | 0.009 | 1 | -0.397 |
2020-09-30 | 0.009 | 1 | -0.466 |
2020-06-30 | 0.008 | 1 | -0.617 |
Adaptimmune Therapeutics plc (ADAP) Company Bio
Adaptimmune Therapeutics plc is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. The company was founded in 2014 and is based in Abingdon, the United Kingdom.
Latest ADAP News From Around the Web
Below are the latest news stories about ADAPTIMMUNE THERAPEUTICS PLC that investors may wish to consider to help them evaluate ADAP as an investment opportunity.
Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past yearKey Insights Institutions' substantial holdings in Adaptimmune Therapeutics implies that they have significant... |
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial SarcomaFirst BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug AdministrationAfami-cel data demonstrate better outcomes for people with synovial sarcoma compared to historical control data; pivotal trial has met primary endpoint for efficacyPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 6, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced the completion of the submission o |
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy INDAdaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma. |
Adaptimmune Receives Transfer of IND for Lete-cel ProgramInterim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma franchise including afami-cel and lete-cel in January 2024Philadelphia, Pennsylvania. and Oxford, United Kingdom--(Newsfile Corp. - November 29, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, announces the transfer of the IND for letetresgene autoluecel |
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerAdaptimmune Therapeutics PLC (ADAP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
ADAP Price Returns
1-mo | 22.50% |
3-mo | 219.57% |
6-mo | 97.32% |
1-year | 31.25% |
3-year | -71.57% |
5-year | -62.21% |
YTD | 85.37% |
2023 | -45.68% |
2022 | -61.07% |
2021 | -30.43% |
2020 | 349.17% |
2019 | -79.13% |
Continue Researching ADAP
Here are a few links from around the web to help you further your research on Adaptimmune Therapeutics PLC's stock as an investment opportunity:Adaptimmune Therapeutics PLC (ADAP) Stock Price | Nasdaq
Adaptimmune Therapeutics PLC (ADAP) Stock Quote, History and News - Yahoo Finance
Adaptimmune Therapeutics PLC (ADAP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...